**Core tip:** Animal and cell culture studies show that statins can damage cerebral gray and white matter, thereby affecting cognitive function. Findings from human studies remain controversial; early observational studies reported that statin use negatively affected cognition, especially memory, while more recent studies have not replicated these findings. Even though statins are widely prescribed for people with type 1 diabetes (T1D), only one study to date has examined whether statin use is related to cognitive impairment in this patient population. We propose that deleterious effects statins may exert on cognition may be more pronounced in people with T1D, as these individuals are already at an increased risk of cognitive impairment due to long-term exposure to metabolic dysregulation.

INTRODUCTION
============

Whether statins negatively affect cognitive function remains under dispute. Goldstein and Mascitelli\[[@B1]\] (2014) propose that statins may negatively affect the brain and cognitive health, potentially *via* impaired myelination. Additionally, cell culture and animal studies show that statins exert neurotoxic effects\[[@B2],[@B3]\]. Four recent meta-analyses/reviews, however, found no significant relationship between statin use and cognitive impairment\[[@B4]-[@B7]\]. While these reviews do acknowledge that statins may negatively impact cognitive function in "vulnerable" populations, they provide no insight as to who may be "vulnerable". We raise the possibility that adults living with type 1 diabetes (T1D) since childhood may fit this "vulnerable" category, for at least two reasons.

First, a growing body of literature recognizes the deleterious effects of T1D on brain structure, with smaller total brain volume reported among those with than those without T1D\[[@B8]-[@B10]\]. Perhaps negative effects of statins of brain function are more pronounced in those with overall smaller brain volume. In other words, those with greater cerebral gray and white matter volumes may be more able to compensate for insults to cerebral gray or white matter related to statin use.

Second, to minimize cardiovascular events, the American Diabetes Association recommends moderate to high intensity statin treatment for diabetic patients at any age who also have atherosclerotic cardiovascular disease, or its risk factors (*e.g*., hypertension, dyslipidemia, overweight/obese), and for all diabetic patients aged 40 years and older, regardless of cardiovascular risk\[[@B11]\]. This means that many T1D patients begin using statins in early adulthood, often before age 30, whereas statin use is relatively uncommon among otherwise "healthy" adults under age 45. While youth with neurofibromatosis 1 or familial hypercholesterolemia also use statins at an early age, the long-term effects of statin use on cognitive function in these patients also remains unclear\[[@B12]\]. In fact, a recent randomized controlled trial recommends against using simvastatin to enhance cognitive function in children with neurofibromatosis 1\[[@B13]\]. Age at initial statin exposure is an important consideration because the brain's white matter continues to undergo myelination well into the 4^th^ decade of life\[[@B14],[@B15]\]. If statins do compromise myelin integrity, then statin use may differentially impact the brain depending on the age at which statin use begins. Additionally, long-term statin use may also reduce the number of glial progenitor cells available for future recruitment as these patients age\[[@B16]\]. Thus, exposure to statins prior to age 40 years, in combination with the metabolic dysregulation that accompanies T1D, may noticeably disrupt brain myelination or myelin integrity, whereas little to no discernable disruption of brain myelin/myelination occurs when delaying exposure to statins until after age 50, and/or in the absence of T1D.

Despite this unique statin use prolife of T1D patients, we found only one study to examine statins and cognitive function in adults with T1D\[[@B17]\]. This small study found no association between statin use and cognitive impairment. However, only 11 out of 55 cases used statins, and duration of statin use was not examined.

We recently documented a higher-than-expected prevalence of cognitive impairment in the middle-aged T1D cohort currently being reported\[[@B18]\], but did not examine statin use as a risk factor for cognitive impairment. This cross-sectional study was therefore conducted to determine whether statin use was associated with cognitive impairment in middle-aged adults with childhood-onset T1D.

MATERIALS AND METHODS
=====================

Participants
------------

This study sample was recruited from the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study, an on-going, prospective observational study of individuals diagnosed with childhood-onset (\< age 17 years) T1D between 1950 and 1980, and drawn from the Children's Hospital of Pittsburgh diabetes registry. During 2010-2013, an MRI eligible subset (108 out of 261 living in the Pittsburgh area, Figure [1](#F1){ref-type="fig"}) participated in an ancillary neuroimaging and neurocognitive study.

![Recruitment of participants with type 1 diabetes from the parent Pittsburgh Epidemiology of Diabetes Complications Study into the ancillary neurocognitive study. EDC: Epidemiology of Diabetes Complications.](WJD-8-286-g001){#F1}

Cognitive assessment
--------------------

Details and results comparing cognitive impairment between this T1D cohort and 138 similarly-aged adults without T1D have been previously published (Nunley et al\[[@B18]\], 2015). In brief, both cohorts underwent a neurocognitive test battery to assess verbal IQ (North American Adult Reading Test); memory \[Rey Auditory Verbal Learning Test - immediate, delay and interference trials, Rey-Osterrieth Complex Figure Delay Task (ROCF-Delay), and Four Word Short Term Memory 5-, 15- and 3-s lists\]; executive function \[Verbal Fluency F-A-S (FAS), Stroop Color-Word (Stroop-CW), Trails Making B (TMTB), Ratio TMTB: TMTA, Letter-Number Sequence\]; psychomotor speed \[Digit Symbol Substitution Test (DSST), Grooved Pegboard (GP), Trail Making Test A (TMTA)\]; semantic fluency \[Verbal Fluency Animals (Animals)\]; and visuo-construction \[Rey-Osterrieth Complex Figure Copy Task (ROCF-copy)\]. In addition to calculating standardized scores for each domain, raw scores on each task were compared to published, demographically-appropriate means\[[@B19]-[@B21]\]. T1D cases performed significantly worse than non-T1D controls on seven tasks: FAS, TMTB, DSST, GP, Stroop-CW, Animals, and ROCF-copy. Any participant scoring 1.5 SD or worse than demographically-appropriate published norms on two or more of these seven tasks met the study definition of cognitive impairment\[[@B18]\]; this classification of cognitive impairment (scores worse than 1.5SD) has been previously validated\[[@B22]\].

Statin use
----------

Participants self-reported all medication use biennially, from parent study baseline (1986-1988) through time of cognitive testing (2010-2013). Statin type was determined using Anatomical Therapeutic Chemical Classification System coding (ATC code): ATC codes C10AA01, 02, and 05, or combination drugs using simvastatin, atorvastatin, or lovastatin, were classified as lipophilic, while codes C10AA03, 04 and 07, or combination drugs using pravastatin or rosuvastatin, were classified as hydrophilic.

Depression/depressive symptoms
------------------------------

Participants completed the Beck Depression Inventory at time of cognitive testing; scores ≥ 10 were categorized as positive for depressive symptoms\[[@B23]\].

Risk factors
------------

Serum total and HDL cholesterol levels were assessed, using standardized methods, at each clinic visit from parent study baseline (1986-1988) to time of cognitive testing (2010-2013); low density lipoprotein cholesterol (LDLc) was calculated using the Friedwald equation. Details on methods of assessing lifestyle/medical factors (*e.g*., blood pressure, diabetes complications, inflammatory markers) have been described elsewhere (for details, see Pambianco et al\[[@B24]\], 2006).

Brain imaging markers
---------------------

Severity of cerebral white matter hyperintensities (Fazekas rating 2-3 *vs* Fazekas 1) served as markers of cerebral small vessel disease; for details of image acquisition and rating of white matter hyperintensities, see Nunley et al\[[@B25]\], 2015. Left hippocampal volume, as a percentage of total intracranial volume, was chosen for these analyses as hippocampal volume is positively related to memory performance; for details of gray matter imaging and segmentation, see Hughes et al\[[@B26]\], 2013.

Statistical analysis
--------------------

Participants with neurocognitive data (*n* = 108) were compared with the remaining 154 participants from the parent study who were MRI ineligible, unable to schedule, or not interested in the neurocognitive study. Data from the parent study's 2004-2006 exam were used to compare participant characteristics, including statin use (yes/no). This time point was selected because it was the most recent physical exam for participants who did not participate in neurocognitive study (*i.e*., only the subgroup participating in the neurocognitive exam underwent a physical exam in 2010-2013, while all participants were offered a physical exam in 2004-2006).

Participants with neurocognitive data were categorized into three groups, based on the distribution of duration of statin use: Never (0 years); 1-6 years; and 7-12 years. This created two groups of ever statin users, split by the median years of statin use. Lipophilic statin use was also determined for all statin users. Characteristics of the three groups were compared using ANCOVA, Fisher exact test, and Jonckheere-Terpstra test as appropriate. *T* tests, Fisher exact, and Wilcoxon Rank-Sum tests compared select factors between participants by cognitive impairment status, as appropriate. Age- and education-adjusted *P* values were obtained from ordinal logistic regression models.

Logistic and linear regression models tested the association between statin use (covariate of interest, with never users as the referent group) and cognitive impairment or cognitive domain z-scores (outcomes). All models controlled for age and education, as we previously demonstrated that education was highly associated with cognitive impairment in this cohort\[[@B18]\]. Each candidate explanatory factor (*i.e*., related to statin use with a *P* ≤ 0.10) was entered individually into the model(s); this approach was necessary due to the high degree of multicollinearity between most factors. Underlying brain pathology markers (white matter hyperintensity severity, left hippocampal volume) were forced separately into the models. To arrive at the most parsimonious models, only factors associated with the outcome at *P* ≤ 0.05 were retained and presented in the tables, controlling for age and education.

Lastly, to account for possible confounding by indication and given the limited sample size of the study, we calculated a propensity score covariate to control for the group difference in statin use. The propensity score was generated based on multinomial logistic regression with the following covariates: Diastolic blood pressure, LDLc, body mass index, smoking history, and history of high blood pressure/using anti-hypertensive medications. Relationships between duration of statin use with cognitive impairment and memory domain z-score were then assessed by logistic regression and linear regression, respectively, while adjusting for the propensity score, age and education.

All participants provided informed consent prior to all study procedures. The University of Pittsburgh IRB approved the study. SAS 9.3 (Cary, NC) was used for data analyses. A biostatistician from University of Pittsburgh Medical Center, Dr. Yuefang Chang, was consulted and contributed to the statistical analyses for this study.

RESULTS
=======

Statin use, duration of statin use, study-average LDL cholesterol, history of high blood pressure, and glycemic control did not differ significantly between those who participated in the neurocognitive study and those unable, ineligible, or refusing participation in the ancillary neurocognitive study (Table [1](#T1){ref-type="table"}, all *P* \> 0.10). Those who agreed to participate had marginally shorter diabetes duration and were generally healthier (*e.g*., lower prevalence rates of retinopathy, neuropathy, microalbuminuria, coronary artery disease) than those who did not participate (Table [1](#T1){ref-type="table"}, all *P* \< 0.02).

###### 

Adults with type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study, by participation status in the ancillary neurocognitive study

                                                                                    **Non-participant (*n* = 154)**   **Participant (*n* = 108)**   ***P* value**
  --------------------------------------------------------------------------------- --------------------------------- ----------------------------- ---------------
  Demographic and lifestyle factors, data are *n* (%), mean ± SD, or median (IQR)                                                                   
  Age (yr)                                                                          51.17 ± 7.74                      49.52 ± 7.04                  0.08
  Female                                                                            86/136 (63%)                      55 (51%)                      0.07
  Years of education                                                                14 ± 2                            15 ± 3                        0.05
  Ever smoking 100 + cigarettes[1](#T1FN1){ref-type="table-fn"}                     57/136 (42%)                      41 (38%)                      0.60
  *ApoE4* (24, 34, 44)                                                              34/151 (23%)                      34 (32%)                      0.12
  BMI (kg/m[2](#T1FN2){ref-type="table-fn"})                                        27.52 ± 4.88                      26.74 ± 4.26                  0.20
  Depressive symptoms[2](#T1FN2){ref-type="table-fn"}                               45/128 (35%)                      23/100 (23%)                  0.06
  Physical activity (Kcal)[3](#T1FN3){ref-type="table-fn"}                          729 (308-1663)                    1009 (448-1966)               0.05
  Type 1 diabetes-related factors                                                                                                                   
  T1D duration (yr)                                                                 37.14 ± 7.20                      35.50 ± 6.32                  0.07
  Age at diagnosis (yr)                                                             8.62 ± 4.10                       8.28 ± 4.11                   0.51
  HbA1c (%)                                                                         7.69 ± 1.69                       7.85 ± 1.85                   0.51
  A1c months (AU)                                                                   1036.38 ± 481.55                  966.82 ± 382.02               0.21
  Insulin sensitivity (eGDR, mg/kg per minute)                                      7.65 ± 2.11                       7.68 ± 2.47                   0.94
  eGFR (mL/min per 1.73 m[2](#T1FN2){ref-type="table-fn"})                          77.49 ± 24.41                     83.31 ± 24.06                 0.09
  Proliferative retinopathy                                                         85/131 (65%)                      51/107 (48%)                  0.009
  Microalbuminuria                                                                  98/133 (74%)                      54/92 (59%)                   0.02
  Coronary artery disease                                                           48 (31%)                          18 (17%)                      0.009
  Cardiac autonomic neuropathy                                                      89/125 (71%)                      48/97 (49%)                   0.001
  Distal symmetric polyneuropathy                                                   86/128 (67%)                      52/100 (52%)                  0.02
  Cardio-metabolic factors                                                                                                                          
  Systolic blood pressure (mmHg)                                                    116 ± 17                          114 ± 16                      0.28
  Diastolic blood pressure (mmHg)                                                   65 ± 10                           66 ± 11                       0.42
  History of high blood pressure[4](#T1FN4){ref-type="table-fn"}                    71 (46%)                          39 (36%)                      0.13
  Total cholesterol (mg/dL)                                                         174.07 ± 34.92                    174.79 ± 35.85                0.88
  LDL cholesterol (mg/dL)                                                           98.15 ± 28.44                     98.48 ± 33.72                 0.94
  HDL cholesterol (mg/dL)                                                           59.89 ± 16.31                     60.63 ± 16.68                 0.74
  Serum creatinine (mg/dL)                                                          1.12 ± 0.67                       1.07 ± 0.61                   0.57
  Ever used statins[1](#T1FN1){ref-type="table-fn"}                                 97 (63%)                          57 (53%)                      0.13
  Years of statin use[1](#T1FN1){ref-type="table-fn"}                               3 (0-6)                           2 (0-8)                       0.44
  Study average LDLc (mg/dL)[1](#T1FN1){ref-type="table-fn"}                        109.95 ± 23.28                    107.65 ± 25.96                0.45
  Inflammatory markers                                                                                                                              
  WBC × 10[3](#T1FN3){ref-type="table-fn"}/mm[2](#T1FN2){ref-type="table-fn"}       6.2 (4.9-7.8)                     6.1 (5.2-6.9)                 0.30
  Adiponectin (μg/mL)                                                               21.1 (15.2-31.0)                  22.2 (15.2-30.1)              0.83
  IL-6 (ng/mL)                                                                      1.4 (0.8-2.3)                     1.3 (0.8-1.8)                 0.42
  TNFα (pg/mL)                                                                      1.3 (1.0-1.9)                     1.3 (1.0-1.8)                 0.92
  C-reactive protein (mg/L)                                                         1.7 (0.9-3.3)                     1.1 (0.6-2.5)                 0.03

Assessed repeatedly from 1986-88 (baseline) through 2004-2006;

Beck Depression Inventory score ≥ 10;

Estimated self-reported weekly activity per modified Paffenbarger questionnaire;

Blood pressure \> 140/80 at any physical exam as part of the parent study and/or any self-reported use of anti-hypertensive medication (1986-2006). Factors assessed in 2004-2006 unless otherwise specified. T1D: Type 1 diabetes; LDLc: Low density lipoprotein cholesterol; BMI: Body mass index; eGDR: Estimated glucose disposal rate; WBC: White blood cell count; IL-6: Interleukin-6; TNFα: Tumor necrosis factor alpha.

Of the 108 with cognitive data, a single participant first reported statin use in 1990-1992; a second participant reported statin use in 1996-1998. Statin use increased at each successive biennial exam, with a total of 57/108 classified as "ever" statin users (Figure [2](#F2){ref-type="fig"}). Of ever statin users, 51/57 (89%) used only lipophilic statins; the small number using hydrophilic statins did not allow for meaningful comparisons by statin type. Of the 51 "never" statin users, six individuals reported using a non-statin alternative (*e.g*., nicotinic acid) to control their cholesterol.

![Numbers of participants with type 1 diabetes in the ancillary neurocognitive study (*n* = 108) who reported using lipid lowering and antihypertensive medications from parent study baseline (1986-1988) through time of cognitive assessment (2010-2012).](WJD-8-286-g002){#F2}

The three statin use groups did not significantly differ (Table [2](#T2){ref-type="table"}, all *P* \> 0.05) in male:female ratio, education, *ApoE4* allele status, estimated weekly physical activity, presence of depressive symptoms, age at T1D diagnosis, serum glucose at time of cognitive testing, prevalent cardiac autonomic neuropathy, distal symmetric polyneuropathy, history of stroke, systolic or diastolic blood pressure, average ankle:brachial index \> 1.3 or non-compressible\[[@B27]\], or concentrations of white blood cell count, adiponectin, or IL-6. Longer duration of statin use was significantly and positively associated with age, BMI, T1D duration, and study-average LDLc concentration, and was significantly and negatively associated with insulin sensitivity (per estimated glucose disposal rate), and kidney function (estimated glomerular filtration rate). Increasing duration of statin use was associated with a lower prevalence of smoking and with a higher prevalence of coronary artery disease and proliferative retinopathy, of having a 14-year average A1c \> 7.5% (\> 58 mmol/mol), and of having a history of high blood pressure or using anti-hypertensive medication (Table [2](#T2){ref-type="table"}, all *P* \< 0.05).

###### 

Comparison of middle-aged adults with type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study by duration of statin use

                                                                                                                             **Never used (*n* = 51)**   **1-6 yr (*n* = 25)**   **7-12 yr (*n* = 32)**   ***P* value[1](#T2FN1){ref-type="table-fn"}**
  -------------------------------------------------------------------------------------------------------------------------- --------------------------- ----------------------- ------------------------ -----------------------------------------------
  Demographic and lifestyle factors, data are *n* (%), mean ± SD, or median (IQR)                                                                                                                         
  Age at cognitive testing (yr)                                                                                              47.5 ± 7.3                  51.8 ± 6.1              51.0 ± 6.7               0.02
  Female                                                                                                                     27 (53%)                    16 (64%)                12 (38%)                 0.10
  Years of education                                                                                                         15 ± 2                      16 ± 3                  14 ± 3                   0.52
  Ever smoking 100+ cigarettes[5](#T2FN5){ref-type="table-fn"}                                                               22 (43%)                    11 (44%)                8 (25%)                  0.05
  *Apo E4* (24, 34, 44)                                                                                                      16 (31%)                    7 (28%)                 11 (34%)                 0.66
  BMI (kg/m[2](#T2FN2){ref-type="table-fn"})                                                                                 26.0 ± 4.3                  27.6 ± 5.1              29.8 ± 4.7               0.002
  Cognitive function                                                                                                                                                                                      
  Cognitively impaired                                                                                                       7 (14%)                     8 (32%)                 15 (47%)                 0.003
  Estimated verbal IQ                                                                                                        108.6 ± 8.2                 107.7 ± 10.0            106.5 ± 6.9              0.24
  Memory domain z-score                                                                                                      0.24 ± 0.75                 -0.23 ± 0.64            -0.25 ± 0.78             0.004
  Executive function z-score                                                                                                 0.18 ± 0.56                 -0.10 ± 0.82            -0.30 ± 0.79             0.06
  Psychomotor speed z-score                                                                                                  0.29 ± 0.66                 -0.33 ± 1.10            -0.28 ± 0.89             0.01
  Visuo- construction z-score                                                                                                0.21 ± 0.64                 -0.16 ± 0.82            -0.21 ± 1.45             0.13
  Type 1 diabetes-related factors                                                                                                                                                                         
  Diabetes duration (yr)                                                                                                     39.6 ± 5.8                  43.4 ± 6.9              42.1 ± 6.5               0.03
  Serum glucose (mg/dL)                                                                                                      188.6 ± 90.5                151.1 ± 73.6            173.0 ± 81.8             0.56
  A1c \> 7.5%, 14-yr average                                                                                                 27 (53%)                    17 (68%)                25 (78%)                 0.02
  Glucose disposal rate (mg/kg per minutr)[2](#T2FN2){ref-type="table-fn"}                                                   8.1 ± 2.0                   7.5 ± 1.8               5.8 ± 2.9                \< 0.001
  Proliferative retinopathy[2](#T2FN2){ref-type="table-fn"}                                                                  17 (33%)                    14 (58%)                20 (63%)                 0.03
  eGFR (mL/min per 1.73 m[2](#T2FN2){ref-type="table-fn"})[2](#T2FN2){ref-type="table-fn"}[4](#T2FN4){ref-type="table-fn"}   91.3 ± 21.1                 79.7 ± 20.1             74.7 ± 27.5              0.02
  Coronary artery disease[2](#T2FN2){ref-type="table-fn"}                                                                    5 (10%)                     3 (12%)                 10 (31%)                 0.02
  Cardiac autonomic neuropathy[2](#T2FN2){ref-type="table-fn"}                                                               21 (47%)                    14 (58%)                13 (46%)                 0.36
  Distal symmetric polyneuropathy[2](#T2FN2){ref-type="table-fn"}                                                            22 (49%)                    13 (57%)                17 (53%)                 0.61
  Cardio-metabolic factors                                                                                                                                                                                
  History of stroke[5](#T2FN5){ref-type="table-fn"}                                                                          1 (2%)                      2 (8%)                  2 (6%)                   0.99
  Systolic blood pressure (mmHg)                                                                                             117.6 ± 12.0                119.6 ± 15.5            123.2 ± 19.3             0.44
  Diastolic blood pressure (mmHg)                                                                                            65.0 ± 9.5                  64.6 ± 9.1              67.5 ± 10.6              0.18
  History of high blood pressure[3](#T2FN3){ref-type="table-fn"}                                                             13 (25%)                    10 (40%)                16 (50%)                 0.04
  Study average LDLc (mg/dL)[5](#T2FN5){ref-type="table-fn"}                                                                 100.3 ± 25.6                112.2 ± 24.9            115.9 ± 24.7             0.02
  Inflammatory markers                                                                                                                                                                                    
  [2](#T2FN2){ref-type="table-fn"}WBC × 10[3](#T2FN3){ref-type="table-fn"}/ mm[2](#T2FN2){ref-type="table-fn"}               5.9 (5.0-6.7)               6.2 (5.2-6.9)           6.2 (5.2-7.1)            0.29
  Adiponectin (μg/mL)[2](#T2FN2){ref-type="table-fn"}                                                                        22.0 (15.7-30.7)            21.8 (14.2-31.4)        22.3 (15.2-28.3)         0.75
  IL-6 (ng/mL)[2](#T2FN2){ref-type="table-fn"}                                                                               1.4 (0.7-1.9)               1.2 (0.8-1.7)           1.2 (1.0-1.6)            0.28
  TNFα (pg/mL)[2](#T2FN2){ref-type="table-fn"}                                                                               1.3 (1.0-2.3)               1.2 (1.0-1.8)           1.3 (1.0-1.6)            0.07
  C-reactive protein (mg/L)[2](#T2FN2){ref-type="table-fn"}                                                                  0.9 (0.6-2.3)               0.9 (0.2-1.6)           1.9 (0.6-4.1)            0.08

*P* values are adjusted for age and education;

Assessed in 2004-2006;

Defined as any EDC assessed SBP \> 140 mmHg or DBP \> 90, or ever self-reported use of anti-hypertensive medication from 1986-1988 through 2010-2013;

Estimated per the Chronic Kidney Disease - Epidemiology (CKD-EPI) formula;

Assessed from EDC baseline (1986-1988) through time of cognitive testing (2010-2013). Factors assessed at time of cognitive testing (2010-2013) unless otherwise specified. T1D: Type 1 diabetes; LDLc: Low density lipoprotein cholesterol; BMI: Body mass index; eGDR: Estimated glucose disposal rate; WBC: White blood cell count; IL-6: Interleukin-6; TNFα: Tumor necrosis factor alpha.

A total of 30/108 (28%) participants met the study definition of cognitive impairment\[[@B18]\] and the percentage of participants with cognitive impairment increased with increasing duration of statin use: 14% of never users, 32% of 1-6 years of statin use, and 47% of 7-12 years of statin use (Table [2](#T2){ref-type="table"}, *P* = 0.003). Longer duration of statin use was significantly related to worse performance on memory (Table [2](#T2){ref-type="table"}, *P* = 0.004) and psychomotor speed (Table [2](#T2){ref-type="table"}, *P* = 0.012), but no other domains (Table [2](#T2){ref-type="table"}, all *P* \> 0.05).

Cognitively impaired participants were significantly more likely to have coronary artery disease, a history of ever using statins, and for a longer duration, than cognitively normal participants, independent of education (Table [3](#T3){ref-type="table"} all *P* \< 0.05). While not statistically significant, cognitively impaired participants were more likely to have a higher study-average LDLc as compared with cognitively normal participants (Table [3](#T3){ref-type="table"}, *P* = 0.063). Associations between cognitive impairment and history of high blood pressure/using anti-hypertensive medication and brain imaging data were not statistically significant (Table [3](#T3){ref-type="table"}, all *P* \> 0.10) (for details regarding relationships between other risk factors and cognitive impairment in this cohort, see references\[[@B18],[@B28]\]).

###### 

Select characteristics^1^ of middle-aged adults with childhood-onset type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study, by cognitive impairment status

                                                                               **Cognitively normal (*n* = 78)**   **Cognitively impaired (*n* = 30)**   ***P* value**
  ---------------------------------------------------------------------------- ----------------------------------- ------------------------------------- ---------------
  Data are *n* (%), mean ± SD, or median (IQR)                                                                                                           
  Coronary artery disease[2](#T3FN1){ref-type="table-fn"}                      9 (12%)                             9 (30%)                               0.02
  Cardio-metabolic risk factors                                                                                                                          
  Ever using statins (1986-2013)[3](#T3FN2){ref-type="table-fn"}               34 (44%)                            23 (77%)                              0.003
  Duration of statin use (statin years)[3](#T3FN2){ref-type="table-fn"}        0 (0-6)                             7 (2-8)                               0.002
  If statin use, only used lipophilic statin[3](#T3FN2){ref-type="table-fn"}   30 (88%)                            21 (91%)                              0.99
  Study average LDLc (mg/dL)[3](#T3FN2){ref-type="table-fn"}                   104.5 ± 25.8                        115.9 ± 24.8                          0.06
  History of high blood pressure[4](#T3FN3){ref-type="table-fn"}               26 (33%)                            13 (43%)                              0.24
  Brain imaging                                                                                                                                          
  Severe White Matter Hyperintensities[5](#T3FN4){ref-type="table-fn"}         17 (26%)                            11 (46%)                              0.09
  Left hippocampal volume[6](#T3FN5){ref-type="table-fn"}                      0.31 ± 0.03                         0.31 ± 0.03                           0.31

Reported *P* value is adjusted for education. ^1^Relationships between other factors and cognitive impairment in this type 1 diabetes cohort have been previously described and published elsewhere (for details, see Nunley et al\[[@B18]\], 2015);

Assessed in 2004-2006;

Assessed since EDC baseline (1986-1988) through time of cognitive testing (2010-2013);

Defined as any EDC assessed SBP \> 140 mmHg or DBP \> 90, or ever self-reported use of anti-hypertensive medication from 1986-1988 through 2010-2013;

Fazekas rating 2-3 *vs* Fazekas rating 1; data on *n* = 89 (for details, see Nunley et al\[[@B28]\], 2015);

Hippocampal volume as a percentage of total intracranial volume, data on *n* = 88 (for details, see Hughes et al\[[@B26]\], 2013). Measures assessed 2010-2013 unless otherwise noted. LDLc: Low density lipoprotein cholesterol.

In logistic regression models with cognitive impairment as the outcome, using statins for 1-6 years, as compared with never using statins, more than tripled the odds of cognitive impairment, but was only marginally significant after controlling for age and education (Table [4](#T4){ref-type="table"}, Model 1). Compared with never using statins, statin use of 7-12 years was related to almost five-fold higher odds of cognitive impairment, independent of age or education (Table [4](#T4){ref-type="table"}, Model 1). Controlling for long-term LDLc, coronary artery disease, or *Apo E4* allele status did not substantially alter the relationship between duration of statin use and cognitive impairment. Furthermore, LDLc, coronary artery disease, and *Apo E4* allele status were not significantly related to cognitive impairment (Table [4](#T4){ref-type="table"}, Models 2-5). Results were overall unchanged when adjusting for white matter hyperintensities or left hippocampal volume (data not shown).

###### 

Results of logistic regression models assessing the association between duration of statin use and cognitive impairment in middle-aged adults with type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study

                    **Variables in Model**           **Cognitive impairment OR (95%CI) *P* value**
  ----------------- -------------------------------- -----------------------------------------------
  Model 1           Never used statins               Referent group
  1-6 yr statins    3.16 (0.93-10.72), *P* = 0.064   
  7-12 yr statins   4.84 (1.63-14.44), *P* = 0.005   
  Model 2           Never used statins               Referent group
  1-6 yr statins    2.86 (0.83-9.86), *P* = 0.095    
  7-12 yr statins   4.26 (1.40-13.00), *P* = 0.011   
  Average LDLc      1.01 (0.99-1.03), *P* = 0.24     
  Model 3           Never used statins               Referent group
  1-6 yr statins    3.29 (0.95-11.40), *P* = 0.061   
  7-12 yr statins   4.13 (1.35-12.60), *P* = 0.013   
  CAD               2.88 (0.88-9.44), *P* = 0.081    
  Model 4           Never used statins               Referent group
  1-6 yr statins    3.14 (0.93-10.64), *P* = 0.066   
  7-12 yr statins   4.95 (1.65-14.82), *P* = 0.004   
  *Apo E4* allele   0.73 (0.26-2.02), *P* = 0.55     
  Model 5           Never used statins               Referent group
  1-6 yr statins    2.90 (0.82-10.29), *P* = 0.099   
  7-12 yr statins   3.69 (1.17-11.68), *P* = 0.026   
  Average LDLc      1.01 (0.99-1.03), *P* = 0.24     
  CAD               2.72 (0.81-9.13), *P* = 0.11     
  *Apo E4* allele   0.75 (0.26-2.15), *P* = 0.59     

Statin use groups: Never used *n* = 51; 1-6 years *n* = 25; 7+ years *n* = 32. Binary outcome: Cognitive impairment present/absent. Model 1: Statin use groups, controlling for age and education; Model 2: Model 1, further controlling for average long-term LDLc (1986-1988 through 2010-2013); Model 3: Model 1, further controlling for prevalent coronary artery disease (CAD); Model 4: Model 1, further controlling for Apo E4 allele status (24, 34, or 44); Model 5: Model 1, further controlling for LDLc, CAD, and Apo E4 allele. LDLc: Low density lipoprotein cholesterol.

In linear regression models with memory domain z-score as the outcome, using statins for 1-6 years was related to half a SD decrease in memory domain score (Table [5](#T5){ref-type="table"}, Model 1) as compared with never using statins. Using statins for 7-12 years was related to almost half a SD decrease in memory domain score (Table [5](#T5){ref-type="table"}, Model 1) as compared with never using statins. Controlling for LDLc, coronary artery disease, or *Apo E4* allele did not substantially alter the relationship between duration of statin use and lower memory domain score, and none of these factors were significantly related to memory domain score (Table [5](#T5){ref-type="table"}, Models 2-5). Results were independent of brain imaging markers (data not shown).

###### 

Results of linear regression models assessing the association between duration of statin use and memory domain function in middle-aged adults with type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study

                    **Variables in Model**   **Memory domain standardized** β**, P value**
  ----------------- ------------------------ -----------------------------------------------
  Model 1           Never used statins       Referent group
  1-6 yr statins    -0.284, *P* = 0.003      
  7-12 yr statins   -0.232, *P* = 0.01       
  Model 2           Never used statins       Referent group
  1-6 yr statins    -0.267, *P* = 0.006      
  7-12 yr statins   -0.209, *P* = 0.031      
  Average LDLc      -0.084, *P* = 0.34       
  Model 3           Never used statins       Referent group
  1-6 yr statins    -0.267, *P* = 0.006      
  7-12 yr statins   -0.213, *P* = 0.032      
  CAD               0.02, *P* = 0.86         
  Model 4           Never used statins       Referent group
  1-6 yr statins    -0.284, *P* = 0.003      
  7-12 yr statins   -0.231, *P* = 0.014      
  *Apo E4* allele   -0.01, *P* = 0.92        
  Model 5           Never used statins       Referent group
  1-6 yr statins    -0.267, *P* = 0.007      
  7-12 yr statins   -0.213, *P* = 0.034      
  Average LDLc      -0.084, *P* = 0.35       
  CAD               0.02, *P* = 0.86         
  *Apo E4* allele   -0.001, *P* = 0.99       

Statin use groups: Never used *n* = 51; 1-6 years *n* = 25; 7-12 years *n* = 32. Outcome: Standardized score of seven tasks assessing memory domain (z-score, in SD units). Model 1: Statin use groups, controlling for age and education; Model 2: Model 1, further controlling for average long-term LDLc (1986-88 through 2010-2013); Model 3: Model 1, further controlling for prevalent coronary artery disease (CAD) as of 2004-2006; Model 4: Model 1, further controlling for *Apo E4* allele status (24, 34, or 44); Model 5: Model 1, further controlling for LDLc, CAD, and *Apo E4* allele. LDLc: Low density lipoprotein cholesterol.

Using propensity score analyses, those using statins for 1-6 years or for 7-12 years were three times more likely to have cognitive impairment as compared with never statin users; the association was borderline significant for those using statins 1-6 years (OR = 3.48, 95%CI: 0.97-12.51; *P* = 0.056) while the association was statistically significant for those using statins 7-12 years (OR = 3.62, 95%CI: 1.05-12.49; *P* = 0.042). Compared with never statin users, using statins for 1-6 years was statistically significantly related to worse memory z-score (Beta: -0.47, SE = 18, *P* = 0.012). While memory domain z-scores were lower for those using statins for 7-12 years than for never users, the difference did not reach statistical significance (Beta: -0.29, SE = 0.18; *P* = 0.12).

DISCUSSION
==========

This study analyzed correlations between statin use and cognitive impairment in a sub-group of participants with T1D from the on-going, observational Pittsburgh Epidemiology of Diabetes Complications Study. These now middle-aged adults were diagnosed with T1D prior to age 18 years, and have reported medication use biennially since the parent study baseline in 1986. Among the 108 participants with a cognitive assessment in 2010-2013, using statins more than tripled the odds of having cognitive impairment discernible by middle age. As duration of statin use increased (never, 1-6 years, 7-12 years), an increasing percentage of participants met the study definition of cognitive impairment (14%, 32% and 47%, respectively), independent of age or education. Depressive symptoms were not associated with statin use, and we have previously shown depressive symptoms were not related to cognitive impairment in this cohort\[[@B28]\]. Results were robust to adjustment for prevalent coronary artery disease, *Apo E4* status, and long-term average LDL cholesterol concentration.

Our results contradict those reported by the only other study we know of to examine relationships between statin use and cognitive function in T1D cohort\[[@B17]\]. This could be due to several factors, including the small number of participants in the prior study who used statins (11 out of 55), the younger age of their participants (mean age 39 years), or that their study population included T1D cases diagnosed in adulthood (diabetes duration ranged from 6-35 years)\[[@B17]\], whereas our cases were all diagnosed in childhood. Furthermore, the prior study did not provide information on duration of statin use in their T1D participants.

That statin use in our cohort was associated with poor performance of memory tasks is of particular interest for three reasons. First, memory problems are the most commonly reported cognitive complaint among statin users\[[@B29]-[@B32]\]. Second, with a mean age of 49 years, our T1D participants should not yet exhibit memory deficits commonly observed in adults ages 65 and older\[[@B33]\]. And third, our findings contradict prior reports that memory appears to be preserved in adult T1D populations\[[@B34]-[@B36]\]. Considering these three points, we believe additional studies are warranted to investigate the cognitive effects of statin use, along with other potential risk factors related to cognitive impairment and poor memory, in adults with childhood-onset T1D. Such studies should employ a longitudinal design, assessing cognitive performance repeatedly, with at least one done prior to initiating statin use, and with detailed ascertainments of statin use (*e.g*., type, dose, age at initiation) over time. We believe this should be a public health priority given that the improved life expectancy of people with T1D\[[@B37]\] will lead to a rapidly-growing population of aging adults with T1D who are at risk of cognitive impairment, with high personal and societal costs.

While confounding by indication cannot be completely ruled out due to study design, we addressed this as best as possible in our statistical approach. Not only were relationships between statin use and cognitive outcomes independent of cardiovascular risk factors, they remained significant when controlling for coronary artery disease, long-term average LDL cholesterol concentration, *Apo E4* status, and two brain imaging measures known to affect cognitive performance. Furthermore, when incorporating the propensity score for statin use, statin use remained statistically significantly related to cognitive impairment, and to poor performance on memory tasks. Thus, based on our previous publication\[[@B18]\] and this study's results, we doubt that associations between statin use and poor cognitive outcomes are due merely to confounding by indication.

We examined statin class (lipophilic *vs* hydrophilic), a factor which may be an important consideration\[[@B31],[@B38],[@B39]\]. However, since almost all participants used lipophilic statins, analyses by statin class were not possible. Even though both classes of statins can cross the blood-brain barrier, lipophilic statins may accumulate in the brain more readily and/or rapidly than hydrophilic statins\[[@B39]\]. The exact nature of how statins affect the brain are unknown, and most of our knowledge is derived from animal or cell culture studies. Animal studies suggest that statins can exert negative impacts on both myelin\[[@B40]-[@B42]\] and neuronal health\[[@B2],[@B3]\]. Other studies report neuroprotective effects of statins\[[@B43]\], while many studies show no effect (see reviews\[[@B6],[@B44]\]). In addition, statins appear to promote cerebral angiogenesis at therapeutic doses, although angiostatic effects occur at higher concentrations\[[@B45]\].

Lastly, our study population differs from those of previous studies assessing statin use and cognitive function in two important ways: Our participants are middle-aged adults who were diagnosed with T1D in childhood, with a median duration of statin use of 6 years. This is in contrast to prior studies which primarily assessed relationships between statins and cognition in overall healthy, elderly adults aged 60 years and older, who used statins for only a short time; most previous cognitive studies examined statin use over periods of less than 3 wk to 1 year, although at least one study examined participants who used statins for 10+ years\[[@B5],[@B6],[@B46]\]. Moreover, these prior studies have not consistently shown evidence of a beneficial effect of statins on cognitive performance. In fact, the British Association for Psychopharmacology recently stated that "until further evidence is available, \...statins (among other drugs)... cannot be recommended either for the treatment or prevention of Alzheimer's disease"\[[@B47]\].

Why are these differences important? First, our participants have been exposed to metabolic dysregulation since childhood, a crucial period of brain development. This might make them more vulnerable to negative consequences of statin therapy than would occur in people without T1D; if diabetes in childhood limited cerebral gray or white matter development, as brain imaging studies suggest, then these individuals may be less able to compensate for statin-related insults to the brain. Second, myelination occurs into early adulthood, with an additional "late wave" of myelination occurring during the 4^th^ decade of life\[[@B48]\]. Exposure to statins during this time may negatively impact the myelination process, and these effects may be most noticeable in people with chronic diseases that negatively impact cerebral white matter development, as appears to occur in people with childhood-onset T1D\[[@B10]\]. Third, most prior studies were conducted in populations with much shorter exposure to statins than our participants have experienced. This is important because statins appear to promote glial progenitor cells to differentiate into oligodendrocytes, accompanied by a loss of uncommitted glial progenitor cells\[[@B16]\]. Thus, initiation of long-term statin use by middle-age, as is recommended for T1D patients, may reduce the pool of progenitor cells for future recruitment, thus making these patients less resilient to cerebral insults from normal aging or T1D-related vascular damage. This, in turn, may contribute to an increased risk for cognitive impairment in this vulnerable patient population.

These results, while compelling, need to be replicated before considering changes in how to best manage lipid profiles and cardiovascular risk in T1D. Limitations of the study include that study design does not allow us to test whether statin use preceded the onset of cognitive impairment. We cannot assess whether cessation of statin treatment would lead to improved cognitive function, particularly on memory tasks, because this is an observational study. Even though T1D duration was not related to cognitive impairment, these results may not be generalizable to middle-aged adults with adult-onset T1D, as such individuals are not exposed to diabetes-related metabolic disturbances during childhood, a critical window of brain development. Strengths of our study include a well-characterized T1D cohort with 25 years of risk factor data, use of an extensive neuropsychological test battery to assess multiple cognitive domains, and inclusion of brain imaging markers known to correlate with cognitive performance.

Identifying modifiable risk factors for cognitive impairment in T1D is an important public health concern because cognitive impairment may negatively impact these individuals' ability to adhere to their diabetes management regime, ultimately leading to higher healthcare costs, increased rates and/or severity of diabetes-related complications, disability, and quality of life issues. It is premature to make decisions about statin use in the management of cardiovascular risk in T1D based solely on the current study findings. At the same time, we encourage clinicians to engage their T1D patients in open dialog to address any concerns over perceived changes in cognitive function.
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COMMENTS
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Background
----------

Type 1 diabetes (T1D) negatively affects cognitive function, but the risk factors contributing to cognitive impairment remain to be elucidated. This is particularly true for middle-aged and older adults living with diabetes since childhood and who are also experiencing the effects of advancing age on cognitive function.

Research frontiers
------------------

Statins are routinely prescribed for primary and secondary prevention of coronary events in people with T1D. Despite the on-going controversy regarding whether statins negatively impact cognitive function, especially the memory domain, there is a lack of data examining statins as a risk factor for cognitive impairment in this patient population.

Innovations and breakthroughs
-----------------------------

As compared to never-statin users, statin use was related to greater odds of cognitive impairment. In addition, statin use was significantly related to lower performance on memory tasks. These relationships were robust to adjustment for coronary artery disease, long-term low density lipoprotein cholesterol levels, ApoE status, education, and age. Confounding by indication was also addressed using propensity score analysis.

Applications
------------

Initiation of long-term statin use by middle-aged adults with childhood-onset T1D may negatively affect cognitive function, with strongest effects on memory. These results should be investigated in other T1D populations, preferentially in longitudinal studies with cognitive assessments and brain imaging assessed pre- and post- statin exposure.

Terminology
-----------

White matter hyperintensities are non-specific brain imaging markers of cerebral small vessel disease and are highly correlated to cognitive impairment and depression in adults ages 65 and older. Different visual rating scales are used to classify their severity; the authors chose the Fazekas scale, with "1" indicating mild white matter hyperintensities, and "2" or "3" indicating moderate to severe white matter hyperintensities.

Peer-review
-----------

This paper aims to test the correlation between statin use and cognitive impairment in adults with childhood-onset T1D, as a group of patients with chronic exposure to metabolic dysregulation. It is a valuable study, and the results are well analyzed.
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